CURATIVE EFFECT EVALUATION OF INTRAPERITONEAL HYPERTHERMIC PERFUSION CHEMOTHERAPY COMBINED WITH APATINIB FOR MALIGNANT ASCITES
LI-PING LIU, XIAO-FENG LI *, QING CHANG, YONG-JUAN WU, KAI LIU, YA-PING JIN, JUN WANG
Tumour Comprehensive Department of Internal Medicine, Baotou Cancer Hospital, Baotou, 014000, China
Download Full Article PDF
This study aims to retrospectively evaluate the curative effect of intraperitoneal hyperthermic perfusion chemotherapy (IHPC) combined with apatinib for malignant ascites of advanced tumours. Twenty peritoneal tumour metastasis patients with ascites were treated with IHPC combined with apatinib. Apatinib was administered at 850 mg daily for four weeks as one cycle. IHPC was applied once a week, for four weeks as a course of treatment. After the initial treatment course of four weeks, indicators of its short-term effect, that is, changes in serum tumour markers CEA, CA125 and CA19-9, as well as ascites volume and scores of Karnofsky performance status (KPS) before and after the treatment, were evaluated
